Benchmarking and transparency: Incentives for the pharmaceutical Industry's Corporate Social Responsibility

Journal of Business Ethics

Volumn 95, Issue 4, 2010, Pages 641-658

  Lee, Matthew ^a   Kohler, Jillian ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

benchmarking; corporate social respon sibility; pharmaceutical industry; socially responsible investing; transparency

Indexed keywords

EID: 77955770833     PISSN: 01674544     EISSN: 15730697     Source Type: Journal    
DOI: 10.1007/s10551-010-0444-y     Document Type: Article

References (55)

1. Benoit, W. L.: 1997, 'Image Repair Discourse and Crisis Communication', Public Relations Review23(2), 177-186.
2. Bradford, J. L. and D. E. Garrett: 1995, 'The Effectiveness of Corporate Communicative Responses to Accusations of Unethical Behavior', Journal of Business Ethics14, 875-892.
3. Brammer, S., C. Brooks and S. Pavelin: 2006, 'Corporate Social Performance and Stock Returns: UK Evidence from Disaggregate Measures, Financial Management35(Autumn), 97-116.
4. Burke, L. and J. M. Logsdon: 1996, 'How Corporate Social Responsibility Pays Off', Long Range Planning29(4), 495-502.
5. BusinessAssurance. com: 2008, 'CEOs Plan to Increase CSR Investments by 25 Percent', http://businessassurance. com/ceos-plan-to-increase-csr-investments-by-25-percent/.
6. Chang, L. B.: 2006, 'Who's in the Business of Saving Lives?'. Journal of Medicine and Philosophy31(5): 461-482.
7. Crook, C.: 2005, 'Thee Good Company', The Economist, January 22, 3-4.
8. Dhanarajan, S.: 2005, 'Managing ethical standards: when rhetoric meets reality', Development in Practice15(3), 529-538.
9. Eden, S.: 1999, We have the facts' - how business claims legitimacy in the environmental debate', Environment and planning A31, 1295-1309.
10. Esteban, D.: 2008, 'Strengthening corporate social responsibility in the pharmaceutical industry', Journal of Medical Marketing, 8(1), 77-79.
11. Flanagan, W. and G. Whiteman: 2007, '"Aids is Not a Business": A Study in Global Corporate Responsibility - Securing Access to Low-cost HIV Medications', Journal of Business Ethics73, 65-75.
12. Fox, T.: 2001, 'Relationships with NGOs Have Been Fundamental to Many Corporations' Social Responsibility Programs', Monday Developments19(17).
13. Fox R. and J. Fox: 2004, 'Organizational Discourse - A language-Ideology-Power Perspective', Praeger, Westport, CT.
14. Frankental, P.: 2001, 'Corporate Social Responsibility - a PR invention? Corporate Communications: An International Journal6(1), 18-23.
15. Franklin, D.: 2008, 'JUST Good Business', The Economist.
16. Friedman, M.: 1970, 'The Social Responsibility of Business is to Increase Its Profits', The New York Times Magazine.
17. Gruskin S., E. J. Mills and D. Tarantola: 2007, 'History, Principles, and Practice of Health and Human Rights', The Lancet370(9585), 449-455.
18. Hartsough, K., D. E. Rosan and L. Sachs: 2006, 'Benchmarking AIDS: Evaluating Pharmaceutical Company Responses to the Public Health Crisis in Emerging Markets', The Corporate Examiner34(6-7).
19. Hemingway, C. A., and P. W. Maclagan: 2004, Managers' Personal Values as Drivers of Corporate Social Responsibility', Journal of Business Ethics50, 33.
20. Kallio, T. J.: 2007, 'Taboos in Corporate Social Responsibility Discourse', Journal of Business Ethics74, 165-175.
21. Kearns, D.: 1986, 'Quality Improvement Begins at the Top', World20(5).
22. Ketola, T.: 2008, 'A Holistic Corporate Responsibility Model: Integrating Values, Discourses and Actions', Journal of Business Ethics80, 419-435.
23. Khosla, R., P. Hunt: 2009, 'Human Rights Guidelines for Pharmaceutical Companies in Relation to Access To Medicines - The Sexual and Reproductive Health Context', Human Rights Centre, University of Essex, Essex.
24. Kolk, A. and R. van Tulder: 2002, International Codes of Conduct: Trends, Sectors, Issues and Effectiveness, Erasmus University, Rotterdam.
25. Lambell, R., G. Ramia, C. Nyland, and M. Michelotti: 2008, 'NGOs and international business research: Progress, prospects and problems', International Journal of Management Reviews10(1), 75-92.
26. Leisinger, K. M.: 2005, 'The Corporate Social Responsibility of the Pharmaceutical Industry: Idealism Without Illusion and Realism Without Resignation', Business Ethics Quarterly15(4), 577-594.
27. Leisinger, K. M.: 2007, 'Corporate Philanthropy: The "Top of the Pyramid"', Business and Society Review112(3), 315-342.
28. Leisinger, K. M.: 2008, 'Corporate Responsibilities for Access to Medicines', Journal of Business Ethics Online, http://www. springerlink. com/content/01011u4800734242/fulltext. pdf.
29. Levy, D. L.: 1999, 'Environmental Management as Political Sustainability', Organization and Environment10(2), 126-147.
30. Maire, J.: 2002, 'A Model of characterization of the performance for a process of benchmarking', Benchmarking9(5), 506-520.
31. Maire, J., V. Bronet, and M. Pillet: 2005, 'A typology of "best practices" for a benchmarking process', Benchmarking12(1), 45-60.
32. Márquez, A., C. J. Fombrun: 2005, 'Measuring Corporate Social Responsibility', Corporate Reputation Review7(4), 304-308.
33. Maynard, M. L.: 2001, 'Policing Transnational Commerce: Global Awareness in the Margins of Morality', Journal of Business Ethics30: 17-27.
34. McWilliams, A. and D. Siegel: 2000, 'Corporate Social Responsibility and Financial Performance: Correlation or Misspecification?' Strategic Management Journal21, 603-609.
35. McWilliams, A. and D. Siegel: 2001, 'Corporate Social Responsibility: A theory of the Firm Perspective', The Academy of Management Review, 26(1), 117-127.
36. McWilliams, A., D. S. Siegel and P. M. Wright: 2006, '"Guest Editors" Introduction - Corporate Social Responsibility: Strategic Implications', Journal of Management Studies43(1).
37. Menou, V., A. Hornstein, and E. Lipton-McCombie: 2008, 'Access to Medicines Index - Ranking Access to Medicines Practices, Access to Medicines Foundation, Haarlem, The Netherlands.
38. Musungu, S. F.: 2006, 'Benchmarking Progress in tackling the challenges of intellectual property, and access to medicines in developing countries', Bulletin of the World Health Organization84(5), 366-370.
39. Oxfam: Investing for Life: 2007, Meeting Poor People's Needs for Access to Medicines Through Responsible Business Practices. Oxfam Briefing Paper No. 109, London, November 27, 2007.
40. Parker, M.: 2003, 'Introduction: Ethics, Politics and Organizing', Organization10(2), 187-203.
41. Pharmaceutical Shareowners Group: 2004, The Public Health Crisis in Emerging Markets: An Institutional Investor Perspective on the Implications of the Pharmaceutical Industry, London: PSG.
42. Porter, M. E., M. R. Kramer: 2006, 'Strategy and Society - The Link Between Competitive Advantage and Corporate Social Responsibility', Harvard Business Review84(12), 78-92.
43. Renneboog, F., J. Ter Horst, and C. Zhang: 2008, 'Socially responsible investments: Institutional aspects, performance, and investor behavior', Journal of Banking & Finance, 32, 1723-1742.
44. Resnik, D. B.: 2001, 'Developing drugs for the developing world: an economic, legal, moral, and political dilemma', Developing World Bioethics1(1), 11-32.
45. Rubin, N.: 2008, 'The Challenge of Socially Responsible Investments', The CPA Journal78(7), 52-55.
46. Sahlin-Andersson, K: 2006, 'Corporate Social Responsibility: A Trend and a Movement, but of What and for What?', Corporate Governance6(5), 595-608.
47. Starr, M. A.: 2008, 'Socially Responsible Investment and Pro-social Change', Journal of Economic Issues42(1), 51-73.
48. Swajkowski E.: 1992, 'Accounting for Organizational Misconduct', Journal of Business Ethics11, 401-411.
49. Sweeney, L., and J. Coughlan: 2008, 'Do different industries report Corporate Social Responsibility differently? An investigation through the lens of stakeholder theory', Journal of Marketing Communications14(2), 113-124.
50. UN: 2005, 'Prescription for Healthy Development: Increasing Access to Medicines', http://www. unmillenniumproject. org/documents/TF5-medicines-Complete. pdf.
51. UN: 2007a, 'Human Rights Guidelines for Pharmaceutical Companies in Relation to Access to Medicines, Draft for Consultation', Report of the UN Special Rapporteur on the Right to Health (19 September 2007).
52. UN Press Release: 2007b, 'UN Independent Expert Launches Draft Human Rights Guidelines for Pharmaceutical Companies' (19 September 2007), http://www. unhchr. ch/huricane/huricane. nsf/view01/497E81A16B31B9C8C125735B0059D7B0?opendocument.
53. Waddock, S., and S. Graves: 1997, 'The Corporate Social Performance - Financial Performance Link', Strategic Management Journal18(4), 303-319.
54. World Bank: 1989, 'Involving Nongovernmental Organizations in World Bank-Supported Activities', World Bank Operational Manual, Operational Directive 14. 70 dated August 28, 1989.
55. Zadek, S.: 2004, 'The Path to Corporate Responsibility', Harvard Business Review82(12), 125-132.